News
tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung cancer (NSCLC). The drug, which targets carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback